These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2960778)

  • 1. Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase.
    Nuutila J; Kaakkola S; Männistö PT
    J Neural Transm; 1987; 70(3-4):233-40. PubMed ID: 2960778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
    Singh A; Naidu PS; Kulkarni SK
    Pharmacology; 2003 Jun; 68(2):81-8. PubMed ID: 12711835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of monoamine oxidase A and B and of catechol-O-methyltransferase inhibition on L-DOPA-induced circling behavior.
    Heeringa MJ; d'Agostini F; DeBoer P; DaPrada M; Damsma G
    J Neural Transm (Vienna); 1997; 104(6-7):593-603. PubMed ID: 9444560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of 3',4'-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum.
    Reches A; Jiang D; Fahn S
    Biochem Pharmacol; 1982 Nov; 31(21):3415-8. PubMed ID: 7150363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats.
    Törnwall M; Männistö PT
    Eur J Pharmacol; 1993 Nov; 250(1):77-84. PubMed ID: 8119326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral effects of deprenyl in aged rats.
    Drago F; Continella G; Spadaro F; Cavaliere S; Scapagnini U
    Funct Neurol; 1986; 1(2):165-74. PubMed ID: 3111946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.
    Reches A; Jiang D; Fahn S
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Jul; 320(1):34-7. PubMed ID: 7121609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.
    Fredriksson A; Archer T
    J Neural Transm Gen Sect; 1995; 102(1):19-34. PubMed ID: 8785021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
    Singh A; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2002; 24(1):23-9. PubMed ID: 11980384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
    Adams CE; Hoffman AF; Hudson JL; Hoffer BJ; Boyson SJ
    Exp Neurol; 1994 Dec; 130(2):261-8. PubMed ID: 7867755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons.
    Storch A; Blessing H; Bareiss M; Jankowski S; Ling ZD; Carvey P; Schwarz J
    Mol Pharmacol; 2000 Mar; 57(3):589-94. PubMed ID: 10692500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
    Engelbrecht I; Petzer JP; Petzer A
    Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
    Bräutigam K; Sohr R; Morgenstern R
    Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation by deprenil of 1-dopa induced circling in nigral-lesioned rats.
    Heikkila RE; Cabbat FS; Manzino L; Duvoisin RC
    Pharmacol Biochem Behav; 1981 Jul; 15(1):75-9. PubMed ID: 6794038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of L-deprenyl on human growth hormone secretion.
    Koulu M; Lammintausta R
    J Neural Transm; 1981; 51(3-4):223-31. PubMed ID: 6793694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
    Soares-da-Silva P; Vieira-Coelho MA; Parada A
    Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.